BR112012008073A2 - compostos heterocíclicos como inibidores de janus quinase - Google Patents

compostos heterocíclicos como inibidores de janus quinase

Info

Publication number
BR112012008073A2
BR112012008073A2 BR112012008073A BR112012008073A BR112012008073A2 BR 112012008073 A2 BR112012008073 A2 BR 112012008073A2 BR 112012008073 A BR112012008073 A BR 112012008073A BR 112012008073 A BR112012008073 A BR 112012008073A BR 112012008073 A2 BR112012008073 A2 BR 112012008073A2
Authority
BR
Brazil
Prior art keywords
formula
compounds
heterocyclic compounds
kinase inhibitors
janus kinase
Prior art date
Application number
BR112012008073A
Other languages
English (en)
Inventor
Minwan Wu
Pravin L Kotian
Tsu-Hsing Lin
V Satish Kumar
Yarlagadda S Babu
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of BR112012008073A2 publication Critical patent/BR112012008073A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

patente de invenção. compostos heterocíclicos como inibidores de jabus cinase. a presente invenção refere-se a compostos de fórmula (i) ou um sal dos mesmo como descrito aqui. a invenção também fornece composições farmacêuticas que compreedem um composto de fórmula (i), intermediários úteis para a preparação de compostos de fórmula i e métodos terapêuticos para a sua pressão de uma resposta imune ou tratamento de câncer ou uma malignidade hematológica usando compostos de fórmula (i).
BR112012008073A 2009-08-27 2010-08-27 compostos heterocíclicos como inibidores de janus quinase BR112012008073A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23754609P 2009-08-27 2009-08-27
US31358310P 2010-03-12 2010-03-12
PCT/US2010/046999 WO2011031554A2 (en) 2009-08-27 2010-08-27 Heterocyclic compounds as janus kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112012008073A2 true BR112012008073A2 (pt) 2016-03-01

Family

ID=43558315

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012008073A BR112012008073A2 (pt) 2009-08-27 2010-08-27 compostos heterocíclicos como inibidores de janus quinase

Country Status (14)

Country Link
US (1) US20120149662A1 (pt)
EP (1) EP2470537A2 (pt)
JP (1) JP2013503191A (pt)
KR (1) KR20120060867A (pt)
CN (1) CN102574863A (pt)
AR (1) AR077990A1 (pt)
AU (1) AU2010292487A1 (pt)
BR (1) BR112012008073A2 (pt)
CA (1) CA2770712A1 (pt)
IL (1) IL218271A0 (pt)
MX (1) MX2012002217A (pt)
RU (1) RU2012111215A (pt)
TW (1) TW201111385A (pt)
WO (1) WO2011031554A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007070514A1 (en) 2005-12-13 2007-06-21 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
RS58449B1 (sr) 2007-06-13 2019-04-30 Incyte Holdings Corp Upotreba soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h- pirazol-1-il)-3-ciklopentilpropionitrila
MX2011001259A (es) * 2008-08-01 2011-03-15 Biocryst Pharm Inc Derivados de piperidina como inhibidores jak3.
AU2010249380B2 (en) 2009-05-22 2015-08-20 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors
EP3643312A1 (en) 2009-05-22 2020-04-29 Incyte Holdings Corporation 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
CN102985417B (zh) 2010-03-10 2015-01-28 因塞特公司 作为jak1抑制剂的哌啶-4-基氮杂环丁烷衍生物
EA035981B1 (ru) 2010-05-21 2020-09-09 Инсайт Холдингс Корпорейшн Композиция ингибитора jak для местного применения
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
EP2640725B1 (en) 2010-11-19 2015-01-07 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012106448A1 (en) * 2011-02-02 2012-08-09 Biocryst Pharmaceuticals, Inc. Heterocyclic compounds as janus kinase inhibitors
WO2012177606A1 (en) 2011-06-20 2012-12-27 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2849357A1 (en) * 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Acyclic cyanoethylpyrazoles as janus kinase inhibitors
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
MD20150037A2 (ro) 2012-11-08 2015-11-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi de dopamină D1
CN113384545A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2017156493A1 (en) 2016-03-11 2017-09-14 Denali Therapeutics Inc. Compounds, compositions, and methods
SI3489239T1 (sl) 2013-03-06 2022-04-29 Incyte Holdings Corporation Postopki in intermediati za pripravo zaviralca JAK
WO2014146249A1 (en) * 2013-03-19 2014-09-25 Merck Sharp & Dohme Corp. Geminally substituted cyanoethylpyrazolo pyridones as janus kinase inhibitors
EA201690357A1 (ru) 2013-08-07 2016-07-29 Инсайт Корпорейшн Лекарственные формы с замедленным высвобождением для ингибитора jak1
UA115388C2 (uk) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
CN103601749B (zh) * 2013-11-26 2016-04-27 大连联化化学有限公司 一种1-烷基吡唑-4-硼酸频哪醇酯的合成方法
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
CN104926816A (zh) * 2014-03-19 2015-09-23 江苏先声药物研究有限公司 一种托法替布类似物及其制备方法与应用
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CN105218548A (zh) * 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途
CN104860872A (zh) * 2015-03-27 2015-08-26 天津药物研究院有限公司 一种双-(3r,4r)-1-苄基-n,4-二甲基哌啶-3-胺l-二对甲基苯甲酰酒石酸盐的合成方法
MX2017013797A (es) * 2015-05-29 2018-03-21 Wuxi Fortune Pharmaceutical Co Ltd Inhibidor de janus quinasa.
KR101730481B1 (ko) 2015-06-01 2017-04-26 엘케이테크넷(주) 지하 매설물 경로 탐지 장치 및 지하 매설물의 위치정보를 제공하기 위한 서버
HU230805B1 (hu) * 2015-12-23 2018-06-28 Egis Gyógyszergyár Zrt Eljárás és köztitermék baricitinib előállítására
MD3472153T2 (ro) 2016-06-16 2022-03-31 Denali Therapeutics Inc Pirimidin-2-ilamino-1H-pirazoli în calitate de inhibitori L RRK2 pentru utilizare în tratamentul tulburărilor neurodegenerative
US20200157081A1 (en) * 2017-05-24 2020-05-21 Denali Therapeutics Inc. Compounds, compositions and methods
EA038912B1 (ru) 2017-08-01 2021-11-09 ТЕРЕВАНС БАЙОФАРМА Ар энд Ди АйПи, ЭлЭлСи Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SI3746429T1 (sl) 2018-01-30 2023-01-31 Incyte Corporation Postopki za pripravo (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
WO2019191684A1 (en) 2018-03-30 2019-10-03 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
JP7083203B2 (ja) * 2018-06-06 2022-06-10 ジェングル セラピューティクス，インコーポレイテッド ピラゾロピリミジン誘導体、その用途並びに医薬組成物
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CA3125039A1 (en) 2019-01-23 2020-07-30 Theravance Biopharma R&D Ip, Llc Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
WO2020161209A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
WO2020161208A1 (en) 2019-02-06 2020-08-13 Syngenta Crop Protection Ag Herbicidal fused pyridazine compounds
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN115028638A (zh) * 2022-06-09 2022-09-09 安徽大学 一种鲁索替尼中间体的制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5041556A (en) 1990-12-11 1991-08-20 American Cyanamid Company Process for the preparation of insecticidal, acaricidal and molluscicidal 2-halopyrrole-3-carbonitrile compounds
US5478830A (en) * 1992-05-29 1995-12-26 The Du Pont Merck Pharmaceutical Company Fused-ring heterocycles for the treatment of atherosclerosis
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
JP3138117B2 (ja) 1993-06-11 2001-02-26 株式会社トクヤマ 新規化合物
JPH06345772A (ja) 1993-06-15 1994-12-20 Tokuyama Soda Co Ltd 新規化合物
JPH07285931A (ja) 1994-04-19 1995-10-31 Tokuyama Corp 新規化合物
CZ20004727A3 (cs) * 1998-06-19 2002-03-13 Pfizer Products Inc. Deriváty pyrrolo[2,3-d] pyrimidinu
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
RU2266905C2 (ru) 1999-09-28 2005-12-27 Эйсай Ко., Лтд. Хинуклидиновые соединения, содержащие их лекарственные средства и способы получения хинуклидиновых соединений
DE19960917A1 (de) 1999-12-17 2001-06-21 Bayer Ag Neue 3-Oxo-2,1-benzisoxazol-1(3H)-carboxamide zur Behandlung von ZNS-Erkrankungen
ATE423120T1 (de) * 2000-06-26 2009-03-15 Pfizer Prod Inc Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
GB0018951D0 (en) 2000-08-03 2000-09-20 Smithkline Beecham Plc Novel compounds
EP1704145B1 (en) * 2004-01-12 2012-06-13 YM BioSciences Australia Pty Ltd Selective kinase inhibitors
FR2881742B1 (fr) 2005-02-10 2007-09-07 Aventis Pharma Sa Pyrroles substitues, compositions les contenant, procede de fabrication et utilisation
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
CN101405282B (zh) * 2006-01-23 2015-03-25 安姆根有限公司 极光激酶调节剂和使用方法
EP2013206A1 (en) 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
GB0608268D0 (en) * 2006-04-26 2006-06-07 Cancer Rec Tech Ltd Therapeutic compounds
MX2009007426A (es) * 2007-01-12 2009-07-17 Astellas Pharma Inc Compuesto de piridina condensado.
CA2681136C (en) * 2007-03-23 2012-05-22 Amgen Inc. Heterocyclic compounds and their uses
ES2734288T3 (es) * 2007-11-28 2019-12-05 Dana Farber Cancer Inst Inc Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
AP2012006192A0 (en) * 2009-10-15 2012-04-30 Pfizer PyrroloÄ2,3-DÜ pyrimidine compounds.

Also Published As

Publication number Publication date
CN102574863A (zh) 2012-07-11
AU2010292487A1 (en) 2012-03-22
AR077990A1 (es) 2011-10-05
KR20120060867A (ko) 2012-06-12
RU2012111215A (ru) 2013-10-10
EP2470537A2 (en) 2012-07-04
WO2011031554A3 (en) 2011-09-15
JP2013503191A (ja) 2013-01-31
MX2012002217A (es) 2012-04-10
CA2770712A1 (en) 2011-03-17
TW201111385A (en) 2011-04-01
US20120149662A1 (en) 2012-06-14
WO2011031554A2 (en) 2011-03-17
IL218271A0 (en) 2012-04-30

Similar Documents

Publication Publication Date Title
BR112012008073A2 (pt) compostos heterocíclicos como inibidores de janus quinase
BR112014012129A8 (pt) inibidores heterocíclicos de glutaminase
GEP20166484B (en) Protein kinase inhibitors
TN2011000263A1 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EA201500278A1 (ru) Пиразолилхиназолиновые ингибиторы киназы
IN2014MN00988A (pt)
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201491824A1 (ru) Производные бензамида для ингибирования активности abl1, abl2 и bcr-abl1
EA201101583A1 (ru) Ингибиторы pi3 киназы или mtor
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112012029994A2 (pt) composto heterocíclicos como inibidores de janus quinase
HK1131608A1 (en) Pyridinone compounds
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
MX2011009796A (es) Inhibidores de la cinasa pi3.
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
EA201300052A1 (ru) [1,8]нафтиридиновые производные
EA201500175A1 (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
BRPI1014802B8 (pt) profármacos de triptolida.
WO2013016720A3 (en) Novel substituted biarylheterocycle derivatives as protein kinase inhibitors for the treatment of cancer and other diseases
MX2013011132A (es) Inhibidor de fosfoinositida 3-quinasa con una porcion de enlace de cinc.
EA201100623A1 (ru) Сульфоксиминзамещенные анилинопиримидиновые производные в качестве cdk ингибиторов, их получение и применение в качестве лекарственных средств
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
BR112014026198A2 (pt) compostos pirazol como inibidores de sglt1

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]